These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 31799745)

  • 21. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
    Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants.
    Shiota M; Dejima T; Yamamoto Y; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Kajioka S; Uchiumi T; Eto M
    Cancer Sci; 2018 Oct; 109(10):3224-3234. PubMed ID: 30051622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
    Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
    Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
    Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
    Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M; Antonarakis ES; Luo J
    Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
    Maughan BL; Antonarakis ES
    Curr Treat Options Oncol; 2015 Dec; 16(12):57. PubMed ID: 26537882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
    Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
    Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB; Ji X; Singh SV
    Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel.
    Sieuwerts AM; Onstenk W; Kraan J; Beaufort CM; Van M; De Laere B; Dirix LY; Hamberg P; Beeker A; Meulenbeld HJ; Creemers GJ; van Weerden WM; Jenster GW; Nieuweboer AJM; Mathijssen RHJ; de Wit R; Martens JWM; Sleijfer S
    Mol Oncol; 2019 Aug; 13(8):1795-1807. PubMed ID: 31180178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
    Antonarakis ES; Armstrong AJ; Dehm SM; Luo J
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):231-41. PubMed ID: 27184811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
    Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
    Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
    Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
    Onstenk W; Sieuwerts AM; Kraan J; Van M; Nieuweboer AJ; Mathijssen RH; Hamberg P; Meulenbeld HJ; De Laere B; Dirix LY; van Soest RJ; Lolkema MP; Martens JW; van Weerden WM; Jenster GW; Foekens JA; de Wit R; Sleijfer S
    Eur Urol; 2015 Dec; 68(6):939-45. PubMed ID: 26188394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.
    Barbier RH; McCrea EM; Lee KY; Strope JD; Risdon EN; Price DK; Chau CH; Figg WD
    Sci Rep; 2021 May; 11(1):10765. PubMed ID: 34031488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells.
    Xu J; Yang X; Deshmukh D; Chen H; Fang S; Qiu Y
    Cells; 2020 Apr; 9(5):. PubMed ID: 32354165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.